FDA Session: HR+ Metastatic Breast Cancer in 2025—Progress, Regulatory Approvals, and the Trials Ahead

Moderator

Laleh Amiri-Kordestani

Moderator

Angela DeMichele, University of Pennsylvania, Philadelphia, PA

2025 FDA Approvals for HR+ Metastatic Breast Cancer

Melanie Royce

2025 FDA Approvals for HR+ Metastatic Breast Cancer

Maria Garcia-Jimenez

Designing Clinical Trials in HR+ Metastatic Breast Cancer: Navigating a Crowded Therapeutic Landscape

Angela DeMichele, University of Pennsylvania, Philadelphia, PA

Panelist

Christy Osgood

Panelist

Stephanie Walker